Mariusz Niemczyk

Medical University of Warsaw

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Leszek Pączek

Institute of Biochemistry and Biophysics, Polish Academy of Sciences

Monika Gradzik

Medical University of Warsaw

Andrzej Kulesza

Medical University of Warsaw

J Wyzgał

Medical University of Warsaw

Magda Fliszkiewicz

Medical University of Warsaw

Stanisław Niemczyk

Wojskowy Instytut Medyczny

Marek Gołębiowski

University of Gdańsk

AŁ

Anna Łabuś

Medical University of Warsaw

Krzysztof Mucha

Medical University of Warsaw

A. Chmura

Medical University of Warsaw

Cooperative Institutions

Medical University of Warsaw

Polish Academy of Sciences

Institute of Biochemistry and Biophysics, Polish Academy of Sciences

University of Warsaw

Institute of Cardiology

Centralny Szpital Kliniczny

Wojskowy Instytut Medyczny

Central Clinical Hospital

Gdańsk Medical University

The Maria Sklodowska-Curie National Research Institute of Oncology

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Ezetimibe in sirolimus-associated hyperlipidemia: To add or not to add to statins?

Annals of Transplantation (2011)

Mariusz Niemczyk Leszek Pączek

Background:Hyperlipidemia is a universal adverse effect of proliferation signal inhibitors (PSI). We report our experience with ezetimibe/statin combined therapy in a case of a kidney transplant recipient receiving sirolimus (SRL)-based immunosuppression. We also present our doubts concerning the need for ezetimibe in kidney transplant recipients on PSI-based immunosuppression.Case Report:Results. In the reported patient, ezetimibe/statin combination therapy successfully decreased cholesterol level.Conclusions:Combined therapy with ezetimibe and statin seems to be effective and safe in transplant recipients with SRL-associated hyperlipidemia. However, well-designed clinical trials should be performed to evaluate if there is an impact of such treatment on the frequency of cardiovascular events and patient survival.

Ezetimibe

Hyperlipidemia

Sirolimus

Immunosuppression

10.12659/aot.882006

Cite

Citations (3)

Renal Transplantation in Autosomal Dominant Polycystic Kidney Disease

EMJ Nephrology (2015)

Andrzej Kulesza Longin Niemczyk Mariusz Niemczyk

Autosomal dominant polycystic kidney disease (ADPKD) affects approximately 1 in 1,000 people in the general population. The natural history of ADPKD includes the progression of chronic kidney disease to end-stage renal disease (ESRD) in a large proportion of patients. Renal transplantation is the treatment modality of choice in these patients. However, there are some specific issues that should be addressed in ADPKD, and the aim of the current review is to describe the issues that need to be considered in the pre and post-transplant management of ADPKD patients, excluding routine procedures.

10.33590/emjnephrol/10311490

Cite

Citations (3)

Glucose and Lipid Metabolism Abnormalities among Patients with Autosomal Dominant Polycystic Kidney Disease

Kidney & Blood Pressure Research (2019)

Magda Fliszkiewicz Mariusz Niemczyk Andrzej Kulesza Anna Łabuś Leszek Pączek

Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent monogenic renal disease with a prevalence of 1:1,000 births and it is the 4th most common cause of dialysis-dependent end-stage renal disease (ESDR). Recent reports suggest an association between APDKD and metabolic derangements, particularly impaired glucose metabolism.In this cross-sectional study we analyzed data obtained from case records of 189 patients with ADPKD, including kidney transplant recipients, managed in an outpatient department.The mean BMI was 25.4 ± 3.9; 25.25 before and 27.7 after transplan-tation. A fasting glucose level above 100 mg/dL (5.6 mmol/L) was observed in 60 patients (29%) - 27% without transplantation and 41% kidney transplant recipients. Diabetes mellitus was diagnosed in 17 patients (8.9%), including 3 (2.3%) without a history of transplantation and 14 (24.1%) after kidney transplantation (p < 0.01). We observed dyslipidemia in 30% and hyperuricemia in 53% of patients.Demonstrated metabolic abnormalities should be considered in maintenance of ADPKD patients, including kidney transplant recipients.

Dyslipidemia

10.1159/000503423

Cite

Citations (3)

Intracranial aneurysms in renal transplant recipients with autosomal dominant polycystic kidney disease

Polskie Archiwum Medycyny Wewnętrznej (2020)

Andrzej Kulesza Monika Gradzik Agnieszka Kulesza Marek Gołębiowski Leszek Pączek

Artificial kidney

10.20452/pamw.15648

Cite

Citations (2)

Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease

American Journal of Neuroradiology (2013)

Mariusz Niemczyk Monika Gradzik Stanisław Niemczyk Maciej Bujko Marek Gołębiowski

ADPKD correlates with an increased frequency of ICANs, but universal screening for ICANs in patients with ADPKD is not currently recommended. The aim of our study was to determine which groups might benefit from screening by determining the prevalence of ICANs in the Polish ADPKD population and identifying any subgroups with an increased risk for ICANs.Eighty-three adult, predialysis-phase patients with ADPKD underwent screening for ICANs with MRA of the brain.The prevalence of ICANs in the studied population was 16.9%, with 6% of the screened group requiring neurosurgical intervention. We also found that the frequency of ICANs increases with age, reaching 22.4% in patients older than 45 years. All diagnosed ICANs were small (< 9 mm) and were localized in the anterior circulation. In addition, MR imaging revealed arachnoid cysts in 4.8% of patients with ADPKD.We suggest that patients older than 45 years with ADPKD be considered as candidates for screening for ICANs, and we propose a clinical algorithm for this subgroup. However, we could not find risk factors for ICANs in younger patients with ADPKD.

10.3174/ajnr.a3456

Cite

Citations (31)

Treatment of Unruptured Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: Primum Non Nocere

American Journal of Neuroradiology (2015)

Mariusz Niemczyk

Autosomal dominant polycystic kidney disease (ADPKD) belongs to the most common genetic disorders, with approximately 12.5 million individuals involved worldwide. The disease is a well-known risk factor for intracranial aneurysms (IAs).[1][1] The rupture of an IA is associated with a high risk of

Primum non nocere

10.3174/ajnr.a4538

Cite

Citations (3)

Corynebacterium coyleae as potential urinary tract pathogen

European Journal of Clinical Microbiology & Infectious Diseases (2019)

Beata Sokół-Leszczyńska Piotr Leszczyński D Lachowicz Olga Rostkowska Mariusz Niemczyk

Corynebacterium coyleae is part of the commensal microflora of the skin, urethra, mucous membranes, and genital tract. Isolates from patients with urinary tract infection (UTI) were reported, but the pathogenic potential of this species has not been defined yet. The aim of the study is to determine whether C. coyleae could be the etiological agent of UTI and to analyze its antibiotic susceptibility. Urine samples were cultured quantitatively according to accepted laboratory procedures. The identification of bacterial isolates was carried out using the Vitek MS (bioMérieux) and antibiotic susceptibility was tested using disc diffusion according to EUCAST guidelines. Between 1 January 2017 and 30 October 2018, a total of 39 C. coyleae strains were isolated. This represented 0.32% of all urine samples cultured in the laboratory during the collection period. The strains were isolated from samples obtained from 35 women and 3 men (age median for all-64 years). One female patient presented with C. coyleae in her urine twice at an interval of 21 months. In six cases of UTI, C. coyleae was isolated in monoculture. The isolates had the same resistance pattern. A total of 11 strains were obtained from cases with a clinical diagnosis of UTI. In 13 cases, the strain was cultured in a monoculture and in 28 cases with accompanying species. All strains were susceptible to vancomycin. However, resistance to ciprofloxacin was observed for 58.4% of the strains. Urine isolates of C. coyleae must be considered as contamination or normal flora in most cases (28/39, 72%). In the remaining cases, it can be considered as potential etiologic agents, mostly in women and especially in the 6 UTI cases where C. coyleae was found as the single culture-positive species. Several of these isolates demonstrate resistance to antibiotics commonly used in empiric treatment of urinary tract infections.

Medical microbiology

Corynebacterium

10.1007/s10096-019-03565-4

Cite

Citations (12)

Sensory neuropathy in a patient with low low‐density lipoprotein cholesterol levels

Geriatrics and gerontology international/Geriatrics & gerontology international (2017)

Mariusz Niemczyk Agata Kusz‐Rynkun Leszek Pączek

10.1111/ggi.12887

Cite

Citations (0)

Tolvaptan in autosomal dominant polycystic kidney disease — a real-life experience

Medical Research Journal (2024)

Julia Maria Borowiecka Leszek Pączek Mariusz Niemczyk

Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic disease of the kidney, leading to end-stage kidney disease (ESKD) in a large proportion of affected individuals. The only approved therapy to slow the progression of chronic kidney disease (CKD) secondary to ADPKD is tolvaptan. The following analysis aimed to present the experience of the centre with tolvaptan used for ADPKD. Materials and methods: Retrospective analysis of single centre data. The study group consisted of 13 patients who started treatment with tolvaptan. The control group consisted of 13 patients who refused to be treated with tolvaptan. Results: In the study group, 2 patients (15%) discontinued tolvaptan due to the side effects. The intention to treat (ITT) analysis showed that among both groups progression of CKD occurred during the observation period. No statistically significant difference in the median change of estimated glomerular filtration rate (eGFR) was noticed between the study and the control group. Moreover, no statistically significant difference in the median change of eGFR was noticed between the pre-study period and the observation period both in the study group and in the control group. Conclusions: According to the following results, tolvaptan is not effective in slowing the progression of CKD in patients with ADPKD in real-life settings. Further observations are needed to confirm these results.

Tolvaptan

End-stage kidney disease

10.5603/mrj.99177

Cite

Citations (0)

Effect of Statins on All-Cause Mortality in Adults: A Systematic Review and Meta-Analysis of Propensity Score-Matched Studies

Journal of Clinical Medicine (2022)

M. Nowak Mariusz Niemczyk Michał Florczyk Marcin Kurzyna Leszek Pączek

Statins are lipid-lowering medications used for the prevention of cardiovascular disease (CVD), but the pleiotropic effects of statins might be beneficial in other chronic diseases. This meta-analysis investigated the association between statin use and mortality in different chronic conditions. Eligible studies were real-world studies that compared all-cause mortality over at least 12 months between propensity score-matched statin users and non-users. Overall, 54 studies were included: 21 in CVD, 6 in chronic kidney disease, 6 in chronic inflammatory diseases, 3 in cancer, and 18 in other diseases. The risk of all-cause mortality was significantly reduced in statin users (hazard ratio: 0.72, 95% confidence interval: 0.66–0.76). The reduction in mortality risk was similar in CVD studies (0.73, 0.66–0.76) and non-CVD studies (0.70, 0.67–0.79). There were no significant differences in the risk reduction between cohorts with different diseases (p = 0.179). The greatest mortality reduction was seen in studies from Asia (0.61, 0.61–0.73) and the lowest in studies from North America (0.78, 0.73–0.83) and Australia (0.78, 0.62–0.97). There was a significant heterogeneity (I2 = 95%, tau2 = 0.029, p < 0.01). In conclusion, statin use was associated with a significantly reduced risk of all-cause mortality in real-world cohorts with CVD and non-CVD.

Standardized mortality ratio

10.3390/jcm11195643

Cite

Citations (23)